Spots Global Cancer Trial Database for compassionate use
Every month we try and update this database with for compassionate use cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | NCT04225429 | Epithelioid Sar... | Tazemetostat | 18 Years - | Ipsen | |
| Expanded Access to Navitoclax | NCT03592576 | Myelofibrosis Acute Lymphocyt... Lymphoblastic L... | Navitoclax Venetoclax | 4 Years - | AbbVie | |
| Expanded Access to Veliparib | NCT03123211 | Solid Tumors Wi... Triple Negative... High Grade Sero... Patients Requir... | Veliparib | - | AbbVie | |
| Expanded Access to ABBV-400 | NCT05982873 | Non-Small Cell ... | ABBV-400 | 18 Years - | AbbVie | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | NCT04507919 | Small Cell Lung... | Dabrafenib Trametininb | 18 Years - 99 Years | Novartis | |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | NCT03414489 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | ABC294640 | 18 Years - | RedHill Biopharma Limited | |
| Compassionate Use Study of Tenalisib (RP6530) | NCT03711604 | Hematological M... | Tenalisib | 18 Years - | Rhizen Pharmaceuticals SA | |
| Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | NCT04225429 | Epithelioid Sar... | Tazemetostat | 18 Years - | Ipsen | |
| Expanded Access for Marizomib | NCT04644107 | Solid Tumor | Marizomib | 18 Years - | Celgene | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Expanded Access to Venetoclax | NCT03123029 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu... | Venetoclax | - | AbbVie | |
| Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine | NCT03025711 | Breast Neoplasm... | 18 Years - 100 Years | Puerta de Hierro University Hospital | ||
| Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients | NCT06279728 | Advanced Non-Sm... Metastatic Non ... | Datopotamab der... | 18 Years - | Daiichi Sankyo | |
| Compassionate Use Study of Tenalisib (RP6530) | NCT03711604 | Hematological M... | Tenalisib | 18 Years - | Rhizen Pharmaceuticals SA | |
| Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) | NCT03414489 | Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... Cholangiocarcin... | ABC294640 | 18 Years - | RedHill Biopharma Limited | |
| Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | NCT04100694 | NRG1 Fusion Pancreatic Canc... Non Small Cell ... Solid Tumor, Un... Prostate Cancer Head and Neck C... Colorectal Canc... Breast Cancer Cholangiocarcin... Renal Cell Carc... Unknown Primary... | MCLA-128 | 18 Years - | Merus N.V. | |
| Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers | NCT00832871 | Cancer | Mifepristone | 18 Years - | New Mexico Cancer Care Alliance | |
| Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers | NCT00832871 | Cancer | Mifepristone | 18 Years - | New Mexico Cancer Care Alliance | |
| Compassionate Use Study of Tenalisib (RP6530) | NCT03711604 | Hematological M... | Tenalisib | 18 Years - | Rhizen Pharmaceuticals SA |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
